QichenSheng Bio Secures Tens of Millions in Pre-A Funding Led by Sunshine Ronghui Capital

VCBeat has learned at the earliest opportunity,Qichen Sheng Biotechnology Co., Ltd. Announces Completion of Tens of Millions in Pre-A Round Financing,Exclusively led by Sunshine Fusion Capital. Qichensheng Biopharma is an innovative pharmaceutical company focused on mRNA therapeutics and related supply chain technologies. It was founded by a team led by internationally renowned senior immunologists, with interdisciplinary expertise spanning genomics, nanoscience, molecular biology, pharmaceutical engineering, and operational management. The proceeds from this financing round will be used to advance the preclinical investigational new drug (IND) applications for two of the company’s mRNA-based innovative drug candidates, support industrialization efforts, and fund the development of subsequent pipeline projects.

Professor He Youwen, Chairman of the Scientific and Technical Committee at Qichensheng Biotechnology, and Chief Technology Officer Li Shiyu stated, “Qichensheng has accumulated extensive experience in mRNA drug development and delivery technologies, boasting an internationally leading mRNA technology platform and GMP-grade mRNA production lines. With the support of Sunshine Ronghui Capital, the company will accelerate the research and development of mRNA-based COVID-19 vaccines and cancer vaccines, while further enhancing its modular mass-production capabilities. The company will assume greater social responsibility, bringing hope for life to patients.”

Liu Dong, CEO of Qichensheng, stated, “The capital injection from Sunshine Ronghui Capital will further support Qichensheng’s rapid development and enhance corporate value. The company will continue to commit itself to becoming a leading enterprise in China’s biopharmaceutical innovation through clear objective management and systematic operational mechanisms.”

Shi Shenghao, Managing Partner of Sunshine Ronghui Growth Fund, stated: “mRNA represents the frontier of international innovative drug development and has already demonstrated significant clinical value in the development of COVID-19 vaccines. Qichensheng Biopharma is dedicated to the development of mRNA technology. Its core team members have accumulated extensive R&D experience in mRNA-related fields, and the company is poised to achieve breakthroughs in mRNA delivery technologies and large-scale manufacturing. With immense future potential, we are delighted to collaborate with the team in committing to delivering innovative mRNA vaccine products to patients.”

Qichensheng Biotechnology Co., Ltd. was established in late 2015, with its headquarters located in Yizhuang, Beijing. It is an innovative mRNA biopharmaceutical company operating at a world-class international standard. The company has completed GMP Nano-mRNA R&D and production facilities in both Beijing and Zhuhai, covering a total area of over 2,000 square meters, enabling efficient modular and customized production of mRNA products.

Centered on mRNA technology, the company has established two core technological platforms: a central “mRNA” pillar flanked by two wings—“cellular” and “nanoparticle” technologies. It achieves in vivo delivery by loading immune cells or lipid nanoparticles (LNPs), boasts extensive R&D experience in mRNA modification patents and LNP delivery systems, and has achieved breakthrough progress. Currently, both of the company’s mRNA product candidates are in the preclinical investigational new drug (IND) application stage, with preclinical data demonstrating significant potential for clinical development. Leveraging its technical expertise in the mRNA field, the company is well-positioned to grow into a leading innovative mRNA therapeutics platform.

Sunshine Ronghui Capital was established in 2015 as one of the pilot entities for insurance-funded private equity management companies, marking the first batch of such initiatives within China’s insurance industry. Since its inception, Ronghui Capital has been built according to market-oriented and professional standards, emerging as one of the most prominent insurance-funded fund management institutions. Under Sunshine Ronghui Capital, business segments include equity investment, real estate investment, and wealth management, with total assets under management approaching RMB 20 billion.

Ronghui Capital’s portfolio of healthcare companies includes Mindray Medical, Yuwell Medical, InnoStar Biology, Lepu Biopharma, Sinocare Pharmaceutical, I-Mab Biopharma, Genor Biopharma, Tongyuan Kang, 3SBio, Sunny Dental, Chaoju Eye Care, and Ruipeng Pet Hospital, among others.